Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Spyre Therapeutics Inc (NASDAQ: SYRE) closed at $30.33 up 1.23% from its previous closing price of $29.96. In other words, the price has increased by $1.23 from its previous closing price. On the day, 0.75 million shares were traded. SYRE stock price reached its highest trading level at $30.39 during the session, while it also had its lowest trading level at $29.4321.
Ratios:
For a deeper understanding of Spyre Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.90 and its Current Ratio is at 10.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on December 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $53.
On December 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $64.
On September 26, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $43.Deutsche Bank initiated its Buy rating on September 26, 2025, with a $43 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 02 ’26 when Turtle Cameron sold 15,000 shares for $30.68 per share. The transaction valued at 460,134 led to the insider holds 671,907 shares of the business.
Turtle Cameron sold 15,000 shares of SYRE for $435,356 on Dec 01 ’25. The Chief Executive Officer now owns 686,907 shares after completing the transaction at $29.02 per share. On Nov 03 ’25, another insider, Turtle Cameron, who serves as the Chief Executive Officer of the company, sold 45,000 shares for $23.33 each. As a result, the insider received 1,049,778 and left with 701,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 2353369344 and an Enterprise Value of 2022991360.
Stock Price History:
The Beta on a monthly basis for SYRE is 3.17, which has changed by 0.24729395 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $35.31, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is 6.34%, while the 200-Day Moving Average is calculated to be 57.63%.
Shares Statistics:
For the past three months, SYRE has traded an average of 954.34K shares per day and 945990 over the past ten days. A total of 77.59M shares are outstanding, with a floating share count of 67.52M. Insiders hold about 12.99% of the company’s shares, while institutions hold 77.23% stake in the company. Shares short for SYRE as of 1765756800 were 11818159 with a Short Ratio of 12.38, compared to 1763078400 on 12464842. Therefore, it implies a Short% of Shares Outstanding of 11818159 and a Short% of Float of 18.4.
Earnings Estimates
Currently, 12.0 analysts are dedicated to thoroughly evaluating and rating the performance of Spyre Therapeutics Inc (SYRE) in the stock market.The consensus estimate for the next quarter is -$0.68, with high estimates of -$0.49 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$0.98 and -$3.37 for the fiscal current year, implying an average EPS of -$2.11. EPS for the following year is -$2.78, with 12.0 analysts recommending between -$0.75 and -$4.55.
